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abstract: Deficiency of the 5-α-reductase enzyme has been found to affect male sexual development. We report 
an 18-year-old patient who was referred to an endocrinology clinic in Jizan, Saudi Arabia, in April 2014 with primary 
amenorrhoea, virilisation and a lack of secondary sex characteristics. As female external genitalia were present at 
birth, she had been raised as a female. Magnetic resonance imaging revealed no uterine or ovarian tissue in the 
pelvis and the presence of a scrotal sac. She was diagnosed with 5-α-reductase type 2 deficiency, a 46,XY disorder 
of sexual development. Typically, affected males have pseudovaginal perineoscrotal hypospadias and ambiguous 
genitalia at birth. Individuals who have been raised as female manifest characteristics of virilisation at puberty, 
including deepening of the vocal tone, phallus enlargement, scrotal hyperpigmentation and increased muscle mass.
Keywords: 46, XY Disorders of Sex Development; Testosterone 5-alpha-Reductase; Dihydrotestosterone; 
Hypospadias; Puberty; Case Report; Saudi Arabia.
18 عاما مت  العمر  تبلغ من  �سجلنا حالة عن مري�سة  للذكور.  التطور اجلن�سي  يوؤثر على  α-5-ريدوكتا�س  اإنزمي  اأن نق�س  امللخ�ص: وجد 
اإحالتها اإىل عيادة الغدد ال�سماء يف جازان باململكة العربية ال�سعودية، يف اأبريل 2014 مع انقطاع الطمث االأويل، والرتجل، وعدم وجود 
يكت�سف  كاأنثى. مل  ن�ساأت  فقد  الوالدة،  عند  لها  لالإناث كانت حا�رشة  اخلارجية  التنا�سلية  االأع�ساء  اأن  ثانوية. ومبا  خ�سائ�س جن�سية 
الت�سوير بالرنني املغناطي�سي اأي ن�سيج للرحم اأو املبي�س يف احلو�س، وتبني وجود كي�س ال�سفن. ومت ت�سخي�سها باأنها م�سابة بالنوع 
الثاين من مر�س نق�س اإنزمي α-5-ريدوكتا�س، XY،46 وهو ا�سطراب يف النمو اجلن�سي. عادة ما يكون لدى الذكور املت�رشرين مهبل كاذب 
وفتحة جمرى البول يف كي�س ال�سفن، واأع�ساء تنا�سلية غري وا�سحة. ويظهر االأفراد الذين متت تن�سئتهم كاإناث �سفات الرتجل يف �سن 
البلوغ، مبا يف ذلك خ�سونة ال�سوت، وت�سخم الع�سو الذكري، وفرط ت�سبغ ال�سفن وزيادة كتلة الع�سالت.
الكلمات املفتاحية: XY،46 ا�سطرابات النمو اجلن�سية؛ الت�ستو�ستريون 5-األفا-ريدوكتا�س؛ ديهدروت�ستو�سرتون؛ فتحة جمرى البول يف كي�س ال�سفن؛ بلوغ؛ 
تقرير حالة؛ اململكة العربية ال�سعودية.
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An 18-year-old patient was referred to an endocrine 
clinic in Jizan, Saudi Arabia, in April 2014 with primary 
amenorrhoea, virilisation and a lack of secondary 
sex characteristics. As female external genitalia were 
present at birth, she had been raised as female. The 
patient reported vocal changes over the course of 
two years, which made her voice sound deeper and 
harsher. Additionally, over the previous year, she had 
experienced unusually thick hair growth on her upper 
and lower limbs as well as the axillary and inguinal 
regions. Her previous developmental history was 
normal. There was no history of consanguinity on the 
part of the parents.
The 5-α-reductase enzyme, also known as 3-oxo-5α-steroid 4-dehydrogenase, converts testosterone to the more physiologically active 
dihydrotestosterone (DHT).1 A deficiency of 5-α- 
reductase results in a rare autosomal recessive 46,XY 
disorder of sexual development caused by mutations 
in the steroid 5-α-reductase 2 (SRD5A2) gene located 
on chromosome 2p23.1,2 Most affected individuals 
have female external genitalia present at birth and are 
raised as female; however, a few patients are adequately 
masculinised by childbirth and are raised as male.2,3 
Due to its rarity, the prevalence of 5-α-reductase type 
2 deficiency in the general population is unknown.4
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On physical examination, the patient communicated 
well, appeared to be comfortable and was not in 
any emotional distress. Her height was 162 cm, she 
weighed 68 kg and her body mass index was 25.9 kg/m2. 
Hair was present on the extensor surfaces of her 
forearms and legs. Breast development corresponded 
to Tanner stage I, while pubic hair growth was categ- 
orised as Tanner stage III. Further physical examin-
ation revealed pseudovaginal perineoscrotal hypo-
spadias and a blind vaginal pouch. The scrotal skin was 
rugose and pigmented with the right gonad palpable in 
the inguinal ligament. The left gonad was 3.2 cm and 
located in the labioscrotal pouch, while the phallus 
was 3 cm in length. The results of a hormonal assay are 
shown in Table 1. 
Magnetic resonance imaging of the pelvis revealed 
no uterine or ovarian tissue. A scrotal sac was 
apparent and contained the left testis which measured 
33 x 24 x 23 mm and was of normal shape and signal 
intensity [Figure 1A]. The undescended right testis 
was located in the right inguinal canal measuring 
31 x 24 x 20 mm and was also of normal shape and 
signal intensity [Figure 1B]. The urinary bladder, 
urethra and seminal vesicles appeared normal. No 
prostatic tissue was identified. A final diagnosis was 
made of a 46,XY disorder of sexual development due 
to 5-α-reductase type 2 deficiency. After extensive 
counselling with the patient and her parents, the 
patient decided to undergo gender reassignment to 
become male.
Discussion
At birth, clinical symptoms of 5-α-reductase type 2 
deficiency range from the appearance of female external 
genitalia to a nearly complete male phenotype; 
however, most patients who present with ambiguous 
genitalia are usually diagnosed in early infancy.5 
The current case describes the late diagnosis of 
5-α-reductase type 2 deficiency in an 18-year-old 
female patient presenting with primary amenorrhoea 
and characteristics of virilisation.
Young children with 5-α-reductase type 2 deficiency 
can either escape diagnosis or be misdiagnosed as 
having partial or complete androgen insensitivity 
syndrome.6 Since biochemical findings can be 
misleading, molecular testing is mandatory to 
identify the underlying cause of a disorder of sexual 
development.6,7 However, measurement of the basal 
serum concentration and the testosterone/DHT 
ratio after puberty is usually sufficient for an accurate 
 
Figure 1: Magnetic resonance imaging (MRI) of the pelvis of an 18-year-old female patient with primary amenorrhoea, 
virilisation and a lack of secondary sex characteristics showing (A) no uterine or ovarian tissue and the presence of a 
scrotal sac (asterisk) containing a left testis of normal shape and signal intensity (arrow) and (B) an undescended right 
testis (arrow) in the right inguinal canal of normal shape and signal intensity. 
Table 1: Hormonal assay results of an 18-year-old 
female patient with primary amenorrhoea, virilisation 
and a lack of secondary sex characteristics
Hormone Result Normal range
Males Females
FSH in mIU/mL 6 2–12 2–12
LH in mIU/mL 7 2–12 2–12
Cortisol in µg/dL 7.2 5.1–19.9 5.1–19.9
Estradiol in pg/mL 42.22 7.6–40.9 12.5–163.5
T in ng/dL 572 200–1,080 10–70
DHT in ng/dL 8 29–76 22–380
DHEA in μg/dL 126 22–640 22–380
AE in ng/dL 127 ≤250 ≤250
T/DHT ratio 67.8 8–16 8–16
17-OHP in ng/mL 0.8 0.1–1.4 0.1–2.9
FSH = follicle-stimulating hormone; LH = luteinising hormone; 
T = testosterone; DHT = dihydrotestosterone; DHEA = dehydro-
epiandrosterone; AE = androstenedione; OHP = hydroxyprogestrone.
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diagnosis of 5-α-reductase type 2 deficiency.8 In 
the present case, the diagnosis of 5-α-reductase 2 
type 2 deficiency was based on the patient’s clinical 
presentation and a hormonal assay which revealed an 
abnormally elevated testosterone/DHT ratio of >60. 
Nevertheless, karyotyping and molecular studies are 
recommended to confirm a homozygous mutation 
of the SRD5A2 gene; unfortunately, this could not be 
performed in the current case.4,7
Many 46,XY individuals raised as females will 
experience psychological difficulties during puberty, 
which results in most affected patients choosing to 
undergo gender reassignment to become male, as in 
the present case.9–11 In such cases, either DHT or high-
dose testosterone therapy should be initiated so as to 
increase the size of the phallus. For patients diagnosed 
after infancy and whose gender identity is definitively 
female, a genitoplasty, prophylactic orchiectomy and 
oestrogen substitution therapy are recommended.12 
Conclusion
Although rare, 5-α-reductase type 2 deficiency should 
be suspected among female patients presenting with 
pubertal virilisation and primary amenorrhoea. Early 
recognition of this condition is critical to avoid 
psychological distress on the part of the patient, 
particularly after puberty. Molecular analysis of the 
SRD5A2 gene should be performed to confirm the 
diagnosis.
